New shot aims to tame severe eczema Flare-Ups
NCT ID NCT06718101
Summary
This study is testing a new injectable drug called lutikizumab for people with moderate to severe atopic dermatitis (eczema). About 80 participants will receive either the drug or a placebo via injection every other week for 16 weeks, followed by the drug for another 32 weeks. The main goal is to see if the treatment safely reduces the severity of skin rashes and intense itching.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Clinical Research Institute /ID# 272558
Tampa, Florida, 33607, United States
-
Arlington Dermatology /ID# 271735
Rolling Meadows, Illinois, 60008, United States
-
Center for Clinical Studies - Clear Lake /ID# 271749
Webster, Texas, 77598, United States
-
Chapel Allerton Hospital /ID# 274762
Leeds, West Yorkshire, LS7 4SA, United Kingdom
-
Clinical Partners /ID# 271791
Johnston, Rhode Island, 02919, United States
-
Clinical Trials Research Institute /ID# 274234
Thousand Oaks, California, 91320, United States
-
Complete Dermatology - Sugar Land /ID# 274240
Sugar Land, Texas, 77479, United States
-
Dermatology Associates of Tyler /ID# 273684
Tyler, Texas, 75703, United States
-
Dermatology Research Associates - Los Angeles /ID# 272945
Los Angeles, California, 90045, United States
-
Encore Medical Research - Weston /ID# 272539
Weston, Florida, 33331, United States
-
Equity Medical, LLC /ID# 272555
New York, New York, 10023-7340, United States
-
Hallym University Kangnam Sacred Heart Hospital /ID# 271785
Seoul, Seoul Teugbyeolsi, 07441, South Korea
-
Health Concepts /ID# 271744
Rapid City, South Dakota, 57702, United States
-
Integrative Skin Science and Research /ID# 274243
Sacramento, California, 95815, United States
-
Konkuk University Medical Center /ID# 271789
Seoul, Seoul Teugbyeolsi, 05030, South Korea
-
Korea University Ansan Hospital /ID# 271786
Ansan-si, Gyeonggido, 15355, South Korea
-
Kyoto University Hospital /ID# 275237
Kyoto, Kyoto, 606-8507, Japan
-
Medical Corporation Kojinkai Sapporo Dermatology Clinic /ID# 273619
Sapporo, Hokkaido, 060-0063, Japan
-
Oregon Dermatology & Research Center /ID# 271733
Portland, Oregon, 97210, United States
-
Orion Clinical Research /ID# 274236
Austin, Texas, 78759, United States
-
Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550
Fountain Hills, Arizona, 85268, United States
-
Research Associates of South Florida /ID# 272549
Miami, Florida, 33134, United States
-
Royal Liverpool University Hospital /ID# 272584
Liverpool, L7 8XP, United Kingdom
-
Royal United Hospital /ID# 274328
Bath, Bath And North East Somerset, BA1 3NG, United Kingdom
-
Seoul National University Hospital /ID# 271787
Seoul, Seoul Teugbyeolsi, 03080, South Korea
-
Skin Care Research Boca Raton /ID# 272544
Boca Raton, Florida, 33486-2269, United States
-
Somnos Clinical Research /ID# 272943
Lincoln, Nebraska, 68510, United States
-
Soon Chun Hyang University Hospital Bucheon /ID# 271788
Bucheon-si, Gyeonggido, 14584, South Korea
-
Tachikawa Dermatology Clinic /ID# 273620
Tachikawa-shi, Tokyo, 190-0023, Japan
-
Western States Clinical Res /ID# 271748
Wheat Ridge, Colorado, 80033-2896, United States
Conditions
Explore the condition pages connected to this study.